Abstract
The relationship between CYP450 and P-gp occurs at different levels. It is known that certain substrates of P-gp undergo metabolic transformations by various CYP450 isoforms; in addition some of them demonstrated to be activators of both P-gp and CYP450. The majority of such compounds are well-known chemotherapeutics, therefore the purpose of this review is to clarify whether there is a relationship between the simultaneous modulation of CYP450 and P-gp and the onset of drug resistance in tumors treatment. Here, we discuss the biological aspects of the topic in relation to the various tissues distribution of CYP450 and P-gp, the recent findings regarding the ability of some chemotherapeutics in modulating both P-gp and CYP450, whether this modulation is ultimately responsible for the onset of drug resistance in cancer treatment and the promising role of gene polymorphisms in determining the interindividual variability in drug responses in clinical practice.
Keywords: Cancer, CYP450, Glycoprotein P, platinum compounds, resistance to chemotherapy, tyrosine kinase inhibitors, chemotherapeutics, Dubin-Johnson syndrome, ATP-Binding Cassette (ABC) proteins, Byler's disease
Current Drug Metabolism
Title: The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Volume: 12 Issue: 8
Author(s): Amalia Azzariti, Letizia Porcelli, Anna Elisa Quatrale, Nicola Silvestris and Angelo Paradiso
Affiliation:
Keywords: Cancer, CYP450, Glycoprotein P, platinum compounds, resistance to chemotherapy, tyrosine kinase inhibitors, chemotherapeutics, Dubin-Johnson syndrome, ATP-Binding Cassette (ABC) proteins, Byler's disease
Abstract: The relationship between CYP450 and P-gp occurs at different levels. It is known that certain substrates of P-gp undergo metabolic transformations by various CYP450 isoforms; in addition some of them demonstrated to be activators of both P-gp and CYP450. The majority of such compounds are well-known chemotherapeutics, therefore the purpose of this review is to clarify whether there is a relationship between the simultaneous modulation of CYP450 and P-gp and the onset of drug resistance in tumors treatment. Here, we discuss the biological aspects of the topic in relation to the various tissues distribution of CYP450 and P-gp, the recent findings regarding the ability of some chemotherapeutics in modulating both P-gp and CYP450, whether this modulation is ultimately responsible for the onset of drug resistance in cancer treatment and the promising role of gene polymorphisms in determining the interindividual variability in drug responses in clinical practice.
Export Options
About this article
Cite this article as:
Azzariti Amalia, Porcelli Letizia, Elisa Quatrale Anna, Silvestris Nicola and Paradiso Angelo, The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy, Current Drug Metabolism 2011; 12 (8) . https://dx.doi.org/10.2174/138920011798357042
DOI https://dx.doi.org/10.2174/138920011798357042 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Genome-wide Differential-based Analysis of the Relationship between DNA Methylation and Gene Expression in Cancer
Current Bioinformatics Antitumor Activity of Cyclodextrin-based Supramolecular Platinum Prodrug In vitro and In vivo
Letters in Drug Design & Discovery Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers
Current Radiopharmaceuticals Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry The Metabolomic Strategy in Tuberculosis Therapy
Combinatorial Chemistry & High Throughput Screening Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry